Na-Yoon Jang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Na-Yoon Jang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Jae-Won Lee
Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Republic of Korea
2 shared publications - Nam-Hyuk Cho
Department of Microbiology and Immunology, Seoul National University College of Medicine, Seoul, Republic of Korea
2 shared publications - Prashant Sharma
Department of Basic Medical Sciences, University of Arizona College of Medicine-Phoenix, Phoenix, USA
2 shared publications - Young Keun Kim
Korea University
2 shared publications - Bum Chul Park
Department of Materials Science and Engineering, Korea University, Seoul, Republic of Korea
1 shared publication - Bum Chul Park
Department of Materials Science and Engineering, Korea University, Seoul 02841, Korea
1 shared publication
Latest Publications
- Open Access
- 15 March 2022
- Published by Elsevier in Cell Reports Physical Science
- Vol. 3 (4) , 100813
Virus blocking textile for SARS-CoV-2 using human body triboelectric energy harvesting
- 15 March 2022
- Published by Elsevier in Cell Reports Physical Science
- Vol. 3 (4) , 100813
Open AccessVirus blocking textile for SARS-CoV-2 using human body triboelectric energy harvesting
- Open Access
- 26 September 2019
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (10) , 493
Application of ZnO-Based Nanocomposites for Vaccines and Cancer Immunotherapy
Engineering and application of nanomaterials have recently helped advance various biomedical fields. Zinc oxide (ZnO)-based nanocomposites have become one of the most promising candidates for biomedical applications due to their biocompatibility, unique physicochemical properties, and cost-effective mass production. In addition, recent advances in nano-engineering technologies enable the generation of ZnO nanocomposites with unique three-dimensional structures and surface characteristics that are optimally designed for in vivo applications. Here, we review recent advances in the application of diverse ZnO nanocomposites, with an especial focus on their development as vaccine adjuvant and cancer immunotherapeutics, as well as their intrinsic properties interacting with the immune system and potential toxic effect in vivo. Finally, we summarize promising proof-of-concept applications as prophylactic and therapeutic vaccines against infections and cancers. Understanding the nano-bio interfaces between ZnO-based nanocomposites and the immune system, together with bio-effective design of the nanomaterial using nano-architectonic technology, may open new avenues in expanding the biomedical application of ZnO nanocomposites as a novel vaccine platform.
- 26 September 2019
- Published by MDPI AG in Pharmaceutics
- Vol. 11 (10) , 493
Open AccessApplication of ZnO-Based Nanocomposites for Vaccines and Cancer Immunotherapy
Engineering and application of nanomaterials have recently helped advance various biomedical fields. Zinc oxide (ZnO)-based nanocomposites have become one of the most promising candidates for biomedical applications due to their biocompatibility, unique physicochemical properties, and cost-effective mass production. In addition, recent advances in nano-engineering technologies enable the generation of ZnO nanocomposites with unique three-dimensional structures and surface characteristics that are optimally designed for in vivo applications. Here, we review recent advances in the application of diverse ZnO nanocomposites, with an especial focus on their development as vaccine adjuvant and cancer immunotherapeutics, as well as their intrinsic properties interacting with the immune system and potential toxic effect in vivo. Finally, we summarize promising proof-of-concept applications as prophylactic and therapeutic vaccines against infections and cancers. Understanding the nano-bio interfaces between ZnO-based nanocomposites and the immune system, together with bio-effective design of the nanomaterial using nano-architectonic technology, may open new avenues in expanding the biomedical application of ZnO nanocomposites as a novel vaccine platform.
- Open Access
- 27 February 2019
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 11 (10) , 4591-4600
Application of radially grown ZnO nanowires on poly-l-lactide microfibers complexed with a tumor antigen for cancer immunotherapy
Zinc oxide (ZnO)-based nanocomposites have shown promising potential for various biomedical applications, including vaccine development, owing to their multifunctionality and biocompatibility. Here, we synthesized radially grown ZnO nanowires (NWs) on poly-L-lactic acid (PLLA) microfibers with unique 3-dimensional structure and applied them as therapeutic cancer vaccines. This inorganic–organic hybrid nanocomposite has mild cellular toxicity but efficiently delivers a tumor antigen into dendritic cells, cellular bridges between innate and adaptive immunity, to stimulate them to express inflammatory cytokines and activation surface markers. We also demonstrated that the hybrid nanocomposites successfully induce tumor antigen-specific cellular immunity and significantly inhibit tumor growth in vivo. ZnO NWs on PLLA fibers systemically reduced immune suppressive TReg cells and enhanced the infiltration of T cells into tumor tissues, compared to mice immunized with PLLA fibers coated with the antigen. Our current findings open a new avenue in extending the biomedical application of inorganic metal oxide-inert organic hybrid nanocomposites as a novel vaccine platform.
- 27 February 2019
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 11 (10) , 4591-4600
Open AccessApplication of radially grown ZnO nanowires on poly-l-lactide microfibers complexed with a tumor antigen for cancer immunotherapy
Zinc oxide (ZnO)-based nanocomposites have shown promising potential for various biomedical applications, including vaccine development, owing to their multifunctionality and biocompatibility. Here, we synthesized radially grown ZnO nanowires (NWs) on poly-L-lactic acid (PLLA) microfibers with unique 3-dimensional structure and applied them as therapeutic cancer vaccines. This inorganic–organic hybrid nanocomposite has mild cellular toxicity but efficiently delivers a tumor antigen into dendritic cells, cellular bridges between innate and adaptive immunity, to stimulate them to express inflammatory cytokines and activation surface markers. We also demonstrated that the hybrid nanocomposites successfully induce tumor antigen-specific cellular immunity and significantly inhibit tumor growth in vivo. ZnO NWs on PLLA fibers systemically reduced immune suppressive TReg cells and enhanced the infiltration of T cells into tumor tissues, compared to mice immunized with PLLA fibers coated with the antigen. Our current findings open a new avenue in extending the biomedical application of inorganic metal oxide-inert organic hybrid nanocomposites as a novel vaccine platform.